ArticleThe World Allergy Organization journal2026
Delayed hypersensitivity reactions to taxanes: Clinical presentation and outcomes of post-medication and rapid drug desensitization.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Taxanes are widely used in solid tumors but may induce delayed hypersensitivity reactions (DHRs), potentially compromising treatment. The aim was to characterize taxane-related DHRs and evaluate the role of post-medication and rapid drug desensitization (RDD) in treatment continuation. Methods: A retrospective, observational study at University Hospital Dr. José Eleuterio González, in Monterrey, Mexico, from January 2020 to May 2025. Patients who developed delayed HSRs following taxane administration were included. After an intravenous challenge test, a post-medication and/or a 3-bag, 12-step rapid drug desensitization (RDD) protocol was applied, adjusted per patient tolerance. Results: Among 4217 patients, 325 (7.7%) developed HSRs; 28 (8.8%) were delayed. Nine cases (32.1%) were attributed to taxanes: 66.6% paclitaxel and 33.4% docetaxel. Most patients were female (88.9%), with a mean age of 52.3 years. The predominant clinical presentation was maculopapular exanthema (77.8%), mainly involving the scalp. Mean time to HSR was 3 days post-infusion, during the second chemotherapy cycle. All patients received 3-7 days of post-medication; 7 of them tolerated the new administration of the drug, while the other 2 underwent a 3-bag, 12-step desensitization. Conclusions: Delayed drug hypersensitivity reactions (DHRs) are a T cell-mediated immune response that occur more than 6 h after exposure, leading to treatment discontinuation or alternative therapies. Management remains poorly defined; however, our findings suggest that pre-medication and RDD may safely support continued chemotherapy. To our knowledge, this is the most extensive reported series of taxane-related DHRs managed with post-medication and RDD in Hispanic population phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.